about
sameAs
The history of tumor virologyCausation and disease: the Henle-Koch postulates revisitedIdentification of a third human polyomavirusHepatitis B Virus e Antigen VariantsHistorical review of the causes of cancerUpdate on Hepatitis B Virus Infection: Focus on TreatmentHepatitis B virus infection: An insight into infection outcomes and recent treatment optionsMouse models of hepatitis B virus infection comprising host-virus immunologic interactionsStatus of hepatitis B virus in the aetiology of uveitis in Great BritainThe alphabet soup of viral hepatitis: is G a new flavi(or) in the mix?Immunodiagnosis of viral hepatitides A to E and non-A to -EHepatitis-associated (Australia) antigen: a reviewViral hepatitis and tests for the Australia (hepatitis-associated) antigen and antibodyCausation and disease: effect of technology on postulates of causationHepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protectionHepatitis B and its Relationship With Oxidative StressStrategies for Human Tumor Virus Discoveries: From Microscopic Observation to Digital Transcriptome SubtractionInduced immunity against hepatitis B virusNew hepatitis viruses: contenders and pretendersComparative virology of primatesMetagenomics for the discovery of novel human viruses.Hepatitis B Virus Immunopathology, Model Systems, and Current TherapiesHepatitis B virus infection. Current concepts of chronicity and immunity.Mendelian inheritance or transmissible agent? The lesson Kuru and the Australia antigen.Update on diagnosis, management, and prevention of hepatitis B virus infection.Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients.Hepatitis B in pregnancy.Oversight and monitoring of blood safety in the United States.Vaccine prevention of cancer: can endogenous antigens be targeted?Viral hepatitis and hepatocellular carcinoma prevention strategy in Japan.Eradication of hepatitis B antigen in fulminant hepatitisBaseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.Sexually transmitted diseases in children: herpes simplex virus infection, cytomegalovirus infection, hepatitis B virus infection and molluscum contagiosumClinical utility of hepatitis B surface antigen levels during the natural history and treatment of chronic hepatitis B infectionHepatitis B virus: where do we stand and what is the next step for eradication?The contribution of virology to contemporary medicineMorphogenesis of hepatitis B virus and its subviral envelope particlesWhat do we need to know about non-A-to-E viral hepatitis?Hepatitis B vaccine: prospects for duration of immunity.Hepatitis B small surface antigen particles are octahedral.
P2860
Q24610004-9A22A394-CD2E-4A13-8B9D-58E2CC64E7F9Q24650408-69D86B6E-7318-4A74-A789-38A62E7148EFQ24672044-F8E5D92E-2EFF-4CB4-8D37-54A7EFD40D97Q24810141-AA2BC5CE-FD87-411D-9F07-77C74515E69CQ26767036-4003A5DF-1BBA-40A9-BF4B-483E055CAAE8Q26781990-175F905D-588E-4848-BE6B-0223916188ECQ26782127-C2B89303-CFAD-4DDB-918B-8622CAFBE9B2Q27002598-BDC9809E-A8EA-45EB-A824-DC52D7028361Q27469348-0AEB75DC-9BF8-4AEC-B559-164277CDEC26Q27472733-837B9AB4-4144-482A-BF65-2D62836BA881Q27477783-13A52253-8851-4BA2-AD7E-D6DB59641EACQ27480919-26AD9CC8-1F44-4667-AFF7-12B0A7163F1FQ27486291-6B14819F-AB58-492F-B531-77FBE4FAE837Q27487371-A8AA2FCC-7D4F-42CD-9783-201894F2B491Q28069273-0B9B9BCC-1770-4B07-8B07-859210A2E72DQ28069754-8B6A8DAD-F066-466D-9B55-A4691811BF97Q28072707-BB6E6F4E-348B-4F0E-A65F-D0878C657749Q28080525-1DD9D45A-294A-4FEF-A8DB-147EA268BCBFQ28201488-71A3A112-CA9B-4032-B22B-E1A3B22E6A8FQ28776105-D23E95F7-AE5C-4F34-8CA3-5F56A1D7E73CQ33530400-7EEA28CD-E30A-4E28-8488-C2C7694FA163Q33559657-E7B9D3F6-9991-40AD-A711-4AE8026B1EA9Q33581104-ED8A10A9-150B-4962-A55B-6DA7AEDEF3A8Q33587885-1C0B09C1-094E-4DEE-ACB0-EE4969C411A7Q33588921-088C1B35-DB6D-4E32-8BB8-C5BA84246B9CQ33590508-5CA9CB65-0F14-4D80-AA91-5E32B595A659Q33617002-E165F960-14A0-4FB8-9F56-5A24B3BD1EE3Q33749419-2D109CA9-0BA8-47BF-B109-18075BF2459EQ33783609-D3AF5034-D893-41BD-BAAD-CBEA78C8C576Q33793052-B42163ED-1A9B-4162-B0D5-561559994394Q33822650-FE82629A-9BE0-44CF-A005-F2E44C1489E7Q33845546-134E39D2-E2C9-4A07-BF79-A3A015385010Q33934491-FB30EAB4-50A7-452C-8CA7-A592DBF4F1CAQ33947471-E43158D3-4AF9-44AB-B18F-A340A3CA1DF8Q33958764-1751F7EA-9695-41AF-90E8-364A2289BCBFQ33998114-329CE57D-5A3F-4BE0-8C9B-8EBFBEF6B277Q34018886-6B8DD4BF-F84A-48B5-8058-E2D25D6957CAQ34027962-1980C704-0735-4EF8-9AFA-18D23B3B3345Q34050389-A6EF03CE-F9D6-4956-B30C-5F436D6AB173Q34078427-5AB8FE85-DE5B-47E3-B822-33AB6658DC68
P2860
description
1965 nî lūn-bûn
@nan
1965 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1965 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1965年の論文
@ja
1965年論文
@yue
1965年論文
@zh-hant
1965年論文
@zh-hk
1965年論文
@zh-mo
1965年論文
@zh-tw
1965年论文
@wuu
name
A "NEW" ANTIGEN IN LEUKEMIA SERA
@ast
A "NEW" ANTIGEN IN LEUKEMIA SERA
@en
A "NEW" ANTIGEN IN LEUKEMIA SERA
@nl
type
label
A "NEW" ANTIGEN IN LEUKEMIA SERA
@ast
A "NEW" ANTIGEN IN LEUKEMIA SERA
@en
A "NEW" ANTIGEN IN LEUKEMIA SERA
@nl
prefLabel
A "NEW" ANTIGEN IN LEUKEMIA SERA
@ast
A "NEW" ANTIGEN IN LEUKEMIA SERA
@en
A "NEW" ANTIGEN IN LEUKEMIA SERA
@nl
P2093
P3181
P1476
A "NEW" ANTIGEN IN LEUKEMIA SERA
@en
P2093
B S BLUMBERG
P3181
P356
10.1001/JAMA.1965.03080070025007
P407
P577
1965-02-15T00:00:00Z